Jonathan Corren

Allergy and Immunology

10780 Santa Monica Boulevard
Suite 280
Los Angeles, CA 90025

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 112 publications

Lessons learned from clinical trials of thymic stromal lymphopoietin (TSLP) inhibition.

Lessons learned from clinical trials of thymic stromal lymphopoietin (TSLP) inhibition.

Journal: The Journal of allergy and clinical immunology

Published: May 28, 2026

Dupilumab efficacy and safety in patients with allergic bronchopulmonary aspergillosis.

Dupilumab efficacy and safety in patients with allergic bronchopulmonary aspergillosis.

Journal: The Journal of allergy and clinical immunology

Published: March 20, 2026

Impact of Sex on Prediction of Asthma Attacks by Clinical Risk Factors and Type 2 Biomarkers.

Impact of Sex on Prediction of Asthma Attacks by Clinical Risk Factors and Type 2 Biomarkers.

Journal: Chest

Published: September 22, 2025

FRONTIER-3: a randomised phase 2a study to investigate tozorakimab, an anti-interleukin-33 monoclonal antibody, in early-onset asthma.

FRONTIER-3: a randomised phase 2a study to investigate tozorakimab, an anti-interleukin-33 monoclonal antibody, in early-onset asthma.

Journal: ERJ open research

Published: February 07, 2025

Lebrikizumab decreases type 2 inflammatory biomarker levels in patients with asthma: data from randomized phase 3 trials (LAVOLTA I and II).

Lebrikizumab decreases type 2 inflammatory biomarker levels in patients with asthma: data from randomized phase 3 trials (LAVOLTA I and II).

Journal: Immunotherapy

Published: January 09, 2025

Inflammatory and clinical risk factors for asthma attacks (ORACLE2): a patient-level meta-analysis of control groups of 22 randomised trials.

Inflammatory and clinical risk factors for asthma attacks (ORACLE2): a patient-level meta-analysis of control groups of 22 randomised trials.

Journal: The Lancet. Respiratory medicine

Published: December 09, 2024

Tezepelumab for the treatment of chronic spontaneous urticaria: Results of the phase 2b INCEPTION study.

Tezepelumab for the treatment of chronic spontaneous urticaria: Results of the phase 2b INCEPTION study.

Journal: The Journal of allergy and clinical immunology

Published: July 17, 2024

The combination of allergen immunotherapy and biologics for inhalant allergies: Exploring the synergy.

The combination of allergen immunotherapy and biologics for inhalant allergies: Exploring the synergy.

Journal: Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology

Published: May 21, 2024

Biomarkers and clinical outcomes after tezepelumab cessation: Extended follow-up from the 2-year DESTINATION study.

Biomarkers and clinical outcomes after tezepelumab cessation: Extended follow-up from the 2-year DESTINATION study.

Journal: Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology

Published: February 14, 2024

Tezepelumab for Severe Asthma: One Drug Targeting Multiple Disease Pathways and Patient Types.

Tezepelumab for Severe Asthma: One Drug Targeting Multiple Disease Pathways and Patient Types.

Journal: Journal of asthma and allergy

Published: October 27, 2023

Tezepelumab for the treatment of severe asthma: a plain language summary of the PATHWAY and NAVIGATOR studies.

Tezepelumab for the treatment of severe asthma: a plain language summary of the PATHWAY and NAVIGATOR studies.

Journal: Immunotherapy

Published: September 29, 2023

Differential modulation of allergic rhinitis nasal transcriptome by dupilumab and allergy immunotherapy.

Differential modulation of allergic rhinitis nasal transcriptome by dupilumab and allergy immunotherapy.

Journal: Allergy

Published: September 20, 2023

Showing 1-12 of 112

Last Updated: 09/26/2026